Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
A Phase II Multicenter Study to Assess the Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
Sponsor: Yonsei University
Terminated
According to the protocol criteria, during the Phase 1 analysis, the registered participants' imaging evaluation responses did not meet the criteria, leading to an early termination
This PHASE2 trial investigates Acral Melanoma and Mucosal Melanoma and is currently terminated or withdrawn. Yonsei University leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Not Yet Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Yonsei University
For direct contact, visit the study record on ClinicalTrials.gov .